Veterinary medicines can sometimes cause unexpected reactions or simply not work as expected — and when that happens, it creates a real challenge for animal health professionals and owners alike. The problem is that without a reliable reporting system, these adverse events can remain hidden, delaying crucial safety improvements and potentially putting animal and public health at risk. That’s exactly why VMD reporting exists: it provides a structured way to capture and escalate real-world safety data to the Veterinary Medicines Directorate, helping regulators detect issues early and maintain confidence in veterinary pharmacovigilance.
Who is required to submit a VMD reporting adverse event report?
Anyone involved in the life cycle of a veterinary medicine in the UK may encounter situations that require VMD reporting. This is part of broader veterinary pharmacovigilance — the systematic monitoring of animal medicinal products to protect animal and public health. Veterinary surgeons, farmers, animal owners, pharmacists and other professionals are encouraged to report any suspected adverse event or lack of efficacy associated with a veterinary medicine. Marketing authorisation holders (MAHs) also have legal responsibilities to record and report adverse events within defined timelines and include them in aggregated safety reports. These requirements ensure that safety signals are identified early and appropriate regulatory action can be taken. According to UK guidance, MAHs must validate reports to ensure minimum essential information is included before submitting them to the VMD. Adverse reports are defined broadly to capture outcomes that are unintended or unfavourable following the use of a veterinary medicinal product, whether used according to instructions or not. Collecting robust real-world data supports continuous benefit–risk assessment and reinforces confidence in treatment safety.
What types of adverse events must be reported to the VMD?
Understanding what must be reported is critical for effective VMD reporting. The UK’s pharmacovigilance framework requires that any adverse event — including unexpected reactions in animals, humans exposed to the product, lack of efficacy, or adverse environmental effects — should be communicated to the Veterinary Medicines Directorate. Adverse events include not just obvious clinical reactions, but also cases where the medicine fails to deliver the expected benefit. These cases may arise from off-label use, product misuse or batch quality concerns, and all must be documented accurately. Reporting these occurrences helps regulators understand trends and develop risk mitigation strategies that sustain safe use.
At Billev Pharma East, we support clients in identifying and categorising these events correctly, ensuring thorough capture of details that meet regulatory expectations. Our expertise ensures that your reports are compliant and informative, contributing to improved pharmacovigilance outcomes.
How does the VMD reporting process work in practice?
The VMD reporting process in the UK is designed to be straightforward but thorough. Reports can be submitted via the VMD’s digital portal, email to the pharmacovigilance team, or in some cases via paper forms if electronic submission isn’t feasible. When an adverse event occurs, the reporter should collect as much clinical information as possible, including details about the animal, the medicinal product, dosing, observed effects, and timing of the event. This narrative underpins the case and supports assessment by the VMD’s pharmacovigilance team.
Once submitted, the VMD reviews incoming reports for completeness and relevance. Cases meeting criteria for seriousness or emerging patterns may be prioritised for further investigation. The information helps inform regulatory decisions, product label updates, or targeted communications to practitioners.
What happens after you submit a VMD report?
Once you complete a VMD reporting submission, the process doesn’t end at “sent.” What happens next determines how the Veterinary Medicines Directorate (VMD) uses your information to monitor the safety and effectiveness of veterinary medicines across the UK. The follow-up stages are designed to ensure that adverse event data contribute meaningfully to pharmacovigilance outcomes.
Here’s a concise view of what happens after you report an adverse event:
| Step | What occurs | Why it matters |
| Report entered | The VMD acknowledges receipt and logs the report into its database. | This creates a permanent record for tracking and trend analysis. |
| Initial review | Pharmacovigilance experts screen the report for completeness and relevance. | Ensures that the data are usable for safety assessment. |
| Classification | Reports are categorised (e.g., animal reaction, human exposure, lack of efficacy). | Helps prioritise serious events or patterns. |
| Follow-up request | VMD may ask the reporter or MAH for more details. | Additional clinical context strengthens evaluation. |
| Trend analysis | Data are analysed alongside other reports to identify signals or clusters. | Supports early detection of safety concerns. |
| Regulatory action | If patterns or serious concerns are identified, the VMD may take action. | Actions can include label updates, guidance to vets, or product restrictions. |
What it means in practice: as soon as your report enters the VMD system, it is logged with a unique reference and stored confidentially. Reports are examined for quality and completeness; if more detail is needed, the VMD will contact you or the Marketing Authorisation Holder (MAH).
The aggregated data from all submissions — including adverse reactions, lack of expected efficacy and environmental impacts — are continuously analysed to spot patterns that single reports might not reveal. This ongoing analysis helps safeguard animal and public health and can lead to regulatory actions that improve product labels or inform veterinary guidance.
By reporting thoroughly and promptly, you help strengthen UK veterinary medicine safety monitoring and support evidence-based decisions within the VMD’s pharmacovigilance framework.
Which information is mandatory when completing a VMD reporting form?
For a valid VMD reporting submission, including the correct minimum information is essential. This typically includes animal species, (age, weight-optional), detailed description of the adverse event, date of occurrence, product name, batch number if available, and the context of usage. Accurate details help regulators evaluate whether the suspected event is linked to the medicine or reflective of other factors such as off-label use. Providing this information clearly reduces follow-up queries and speeds up assessment. In practice, recording a concise but thorough narrative of the event — with supporting clinical facts — makes the report more useful for pharmacovigilance professionals analysing patterns or signals across multiple submissions.
Where and how can you submit a VMD adverse event report online?
To initiate VMD reporting, visit the official UK government portal dedicated to reporting veterinary medicine problems. Here, you can fill out an electronic form designed to capture essential adverse event information, upload supporting documentation, and submit directly to the VMD’s pharmacovigilance team.
The UK’s digital system simplifies submissions and ensures timely processing. In most cases, electronic reporting is mandatory for marketing authorisation holders, while email submissions are available for specific circumstances. Practitioners should retain copies of submissions for their records and be prepared to provide follow-up information if requested by the VMD to clarify details or expand on initial reports.
Where can you file your VMD report online?
Once you’re ready to complete VMD reporting of a suspected adverse event or lack of expected efficacy with a veterinary medicine, the UK provides an official digital submission route that ensures your information goes directly to the Veterinary Medicines Directorate (VMD). You can use the government’s dedicated online service to report a problem with an animal medicine — this includes cases where a medicine didn’t work as expected or caused a reaction in an animal or person.
This online reporting page is the primary way that individuals, veterinary professionals and other stakeholders can provide their case details to the VMD. The system guides you through entering key information about the product involved, the circumstances of use and the effects observed so that the VMD can process your submission effectively. While the online form is the main route, you can also contact the VMD pharmacovigilance team by email if you need further help or clarification on the reporting process. Submitting via the official online portal helps ensure that your VMD reporting contributes directly to UK veterinary pharmacovigilance efforts and supports regulators in monitoring medicine safety and taking appropriate action when necessary.
What happens after a VMD reporting submission is made?
After completing VMD reporting, the VMD reviews the submission to ensure it contains sufficient information for pharmacovigilance assessment. Reports are evaluated based on severity, frequency, and potential causal links to the medicinal product. If additional information is needed, the VMD may contact the reporter or the marketing authorisation holder to clarify data or request supporting evidence. Serious or recurring patterns may lead to regulatory action, such as label changes or safety communications. All reports contribute to broader safety monitoring databases and help shape UK veterinary medicine policy and guidance for best practices in animal healthcare.
What are the most common mistakes to avoid in VMD reporting?
Common pitfalls in VMD reporting include incomplete data, missing timelines, unclear descriptions of the adverse event, or failure to include batch information. Such gaps may delay assessment or require follow-ups that prolong the process. Another frequent issue is misclassification of events or overlooking lack of efficacy cases as reportable. Remember that any unexpected outcome — whether it’s a lack of expected efficacy or an unusual reaction — should be documented. Reporters should also avoid duplicating submissions with the marketing authorisation holder; instead, coordinate to ensure one comprehensive report is shared with the VMD, supported by accurate clinical narrative.
Read also:
- How do the UK veterinary medicines regulations define pharmacovigilance obligations for MAHs?
- Why do underreporting trends remain one of the core challenges in veterinary pharmacovigilance?
- How can you distinguish a veterinary adverse event from normal pharmacological effects?
Sources: 1 – GOV.UK. (2025). Guideline III: Adverse event reporting – pharmacovigilance of veterinary medicines in Great Britain, 2 – GOV.UK. (n.d.). Report a suspected problem with an animal medicine or microchip, 3 – VMD Connect. (n.d.). Adverse events – VMD Connect resource, 4 – VMD Digital Services. (n.d.). Access Veterinary Medicines Digital Services for reporting, 5 – NOAH Compendium. (n.d.). Adverse reactions and pharmacovigilance in the UK, 6 – VMD Connect. (n.d.). Reporting guidance and resources, 7 – GOV.UK. (n.d.). Pharmacovigilance of Veterinary Medicinal Products in Great Britain, 8 – GOV.UK. (n.d.). Contact VMD – report an adverse reaction to veterinary medicine.
Image credits
In-article image: Photo by Tima Miroshnichenko by Pexels
In-article image: Photo by Tima Miroshnichenko by Pexels
Hero image: Photo by Gustavo Fring by Pexels